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Abstract:
Human embryonic stem cells (hESCs) and hESC-derived cells are of great interest, not only because of their therapeutic potential, but also their prospective uses in in vitro drug and toxicity screening. The ability to preserve these cells is critical, allowing for the generation of quality controlled stocks of cells, transport of cells between sites and avoiding the need for expensive and time consuming continuous culture. Current methodologies, namely conventional slow freezing and vitrification, can successfully preserve hESCs and their differentiated progeny, retaining the key characteristics of the cells. However, there is a significant gap between the number of cells potentially needed to either treat patients or run a high-throughput drug screen and how many cells can be preserved using these techniques.
Therefore, this review focuses on the scalability of slow freezing and vitrification, identifying key barriers to success and whether they can be overcome. Given the precedent with other mammalian cells in using slow freezing to successfully preserve large quantities of cells, and its compatibility with current and emerging culture methods for hESCs, it is likely to become the method of choice for cryopreserving these cells at scale. However, issues other than scale still exist, therefore alternatives to cryopreservation should also be explored. Here, the potential to lyophilise hESCs for long-term storage is considered as one such alternative.
Introduction
Human embryonic stem cells (hESCs) hold great promise in the field of regenerative medicine. These cells have the ability to self-renew and are pluripotent, meaning that, given the right stimulus, they have the ability to differentiate into almost any cell type of the body, such as cardiomyocytes, pancreatic β-cells, hepatocytes or neurons. The potential of such hESCderived cells as therapeutic agents has recently been highlighted by the start of some long-awaited clinical trials in both the UK and USA. 1 Human ESCs and hESC-derived cells are also of great interest for the in vitro study of: development, genetic disorders 2 and use in drug discovery or toxicology studies. 3, 4 For example, a high-throughput screen (HTS) was recently used to identify compounds that regulate hESC self-renewal and differentiation, 5 supporting the use of these cells in HTS assays. In another study it was found that hESC-derived cardiomyocytes can accurately indicate some adverse drug effects. 6 This suggests that if further developed, such systems could be used in drug safety testing as well as initial drug screening, potentially cutting down on the need for some animal testing. Indeed, hESCderived cardiomyocytes for in vitro assays can now be purchased from a commercial source.
Human ESCs are dependent on attachment to a matrix, provided by either a feeder layer of cells or an extracellular matrix substitute, for growth.
Typically, they are grown as colonies in planar culture, although growth in monolayer culture can also be achieved. [7] [8] [9] [10] It has been estimated that 10 9 cardiomyocytes are needed to repair a single infarcted heart, 11 but given the current inefficiency of both differentiation and separation protocols, the number of hESCs needed is likely to be closer to 10 13 . Thus, in order to meet the potential demand for these cells, much of the current hESC research is focused on developing defined and scalable culture methods as well as directing differentiation in order to generate relevant cell types. However, it is also important to consider how, once produced, both hESCs and their derived products will be preserved at scale.
As discussed in more detail in Section 2, preservation of these cells is critical to storing high quality stocks for either clinical or in vitro applications. Figure 1 shows that cells can be preserved at different points along the manufacturing plated in order to screen a library of 1 million compounds in a HTS campaign. 5 Even assuming 100% of cells are recovered post-preservation, which is often not the case, using current methodologies appreciably fewer cells can be cryopreserved. This means that some cell culture is required between thawing cells and using them in therapy or HTS campaigns which is not ideal.
For instance, one study stored up to 3x10 6 hESCs/cryostraw using a slowfreezing protocol 14 and significantly fewer hESCs can be preserved by vitrification, although exact numbers can be difficult to ascertain. Human
ESCs are vitrified in clumps and, even when the numbers of cells/clump are determined, this can vary considerably from 100 to 400. 15, 16 Given the current gap between the numbers of cells required and the capacity of current technologies to preserve hESCs and hESC-derived cells, the focus of this review is the scalability of conventional slow freezing and vitrification.
Key barriers which limit the potential for either scale-up or scale-out of these methods are identified and discussed. Furthermore, as scalability is not the only issue that should be considered when choosing a preservation technique, the suitability of lyophilisation to preserve hESCs and their differentiated progeny is also explored.
Why preserve hESCs and their differentiated progeny?
Human ESCs and hESC-derived cells are preserved for a number of different reasons. Firstly, preservation allows for transport of cells between or across sites. This is critical for storage and distribution facilities such as national stem cell banks and companies with multiple research or manufacturing sites.
In addition, it also allows manufacturers of cellular therapies to develop business models where the production is spatially and temporally removed from the clinic. As already mentioned, cryopreservation is the most widely used preservation method for mammalian cells, including hESCs and hESC-derived cells. The dangers associated with freezing cells include intracellular ice crystal nucleation and osmotic stresses (depicted in Figure 2 ), which can result in a loss of cell viability and/or affect cell function. [22] [23] [24] [25] Indeed, ideally the formation of intracellular ice should be avoided and intracellular vitrification encouraged. 23 Therefore, two different freezing methods have been developed which aim to overcome these hurdles through the use of specific freezing rates and cryoprotective agents (CPAs): conventional slow freezing, in which the extracellular solution is frozen but the formation of intracellular ice is minimised, and vitrification, in which the formation of any ice crystals is avoided. These methods are briefly outlined in Figure 3 (for in-depth reviews on aspects of cryobiology, including the role of CPAs and manual ice seeding, please refer to [22] [23] [24] [25] [26] ). In all cases of cryopreservation, cells are recovered by means of a rapid thaw to reduce the risk of developing damaging ice crystals during thawing.
Vitrification
Vitrification is a method by which clumps of cells are placed in a cryoprotective medium and rapidly cooled by plunging samples into liquid nitrogen so that both extracellular and intracellular ice formation is avoided.
The glass-phase transition temperature of water is -138°C and vitrification of pure water can only take place at a cooling rate of 10 6°C /sec or above. 22 Therefore, in order to achieve vitrification of cell clumps at more modest rates, thermal mass is minimised and high concentrations of CPAs (~4M) are used. 27 The presence of high concentrations of CPAs act to increase the viscosity, decrease rate of nucleation and ice crystal growth and increase the glassphase transition temperature of the solution such that vitrification can occur at achievable cooling rates. 22, 25 Although successfully used to preserve embryos 28 and hESCs (Section 3.2), vitrification does have its disadvantages. Because rapid cooling rates must be achieved, only small volumes, typically 1-20 μl, may be vitrified, making this an extremely low-throughput process. The high concentrations of CPAs (~4M), such as dimethylsulfoxide (DMSO), ethylene glycol and 1,2-propanediol, used to achieve vitrification can also be highly toxic. 27, 29 Furthermore, CPAs require a step-wise loading protocol 29, 30 to avoid exposing the cells to osmotic imbalances, making protocols very labour intensive.
Vitrification protocols which use lower concentrations of CPAs are, however, being developed. Cryostraws or loops are commonly used to vitrify cells and cooling rates of only ~20,000°C/min can be achieved, 31 necessitating the use of high concentrations of CPAs. Recently, the use of quartz microcapillaries has enabled higher cooling rates (> 100,000°C/min) to be achieved and relatively low concentrations of CPAs (2M 1,2-propandiol and 0.5M trehalose)
to be used in the preservation of mouse ESCs. 27 Furthermore, the use of quartz microcapillaries in combination with cell encapsulation technology, has also enabled the vitrification of mouse mesenchymal stromal cells in even lower concentrations of DMSO (~1.5M).
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Although this does reduce exposure of cells to toxic agents, the need to use small volumes and/or a large surface area remains an absolute requirement in order to enable vitrification at easily achievable cooling rates. Therefore, the potential to scale up the process is still very limited. As will be mentioned in Section 3. propanediol and 0.5M trehalose). 34 Although multiple step CPA loading and unloading processes were still used, the set-up used could potentially be automated, making it an attractive option for larger scale vitrification of cells.
Vitrification of hESCs
Human ESCs grown in colonies, as opposed to monolayers, have typically been vitrified using an OPS technique as outlined in Figure 4 . High levels of cell recovery (>75%) have been recorded using this protocol, particularly when compared with some of the early attempts at preserving hESCs using slow freezing, 15, 16, 35 making this a popular choice. In addition, in order to overcome the issues of sterility in such an open system and make it more GMP compatible, closed vitrification protocols have been developed. 16 Although vitrified hESCs retain their ability to grow as colonies and differentiate upon thawing, the major drawback of using this method is the small number of cells that can be preserved per cryocontainer. Unfortunately, poor recovery rates of only 12% 36 and ~20% 37 currently make this method nonviable without a great deal of optimisation.
More recently, a cell strainer has been used to vitrify hESCs colonies as this could hold a large number of clumps at once whilst retaining a rapid cooling rate once plunged into liquid nitrogen. 33 Although cells were successfully preserved, with high survival rates and retention of pluripotency, this new carrier was bulky and irregular in shape making it hard to manipulate and store. Since then, Li and colleagues have devised an alternative cryocontainer, which is based on a 1 ml cryovial modified to contain a cell strainer, to overcome this. 17 Using this modified vial these workers were able to preserve 20 times more hESC clumps per straw than in the OPS method.
Nonetheless, assuming a maximum of 400 cells/clump (based on numbers in 16 ), this amounts to <5x10 4 Although relatively low concentrations of CPAs are used (typically <1.5M), most, including DMSO, are still toxic to cells, particularly at temperatures above 0°C 23, 30 and thus exposure at room temperature must be limited. This is achieved by rapidly commencing the freezing process before preservation and diluting out the CPAs from the cell mixture upon thawing.
Step-wise loading protocols can also be used to minimise osmotic shock to the cells.
On a laboratory scale, 1-10x10 6 cells in 1 ml of cryopreservation medium in a 1-2 ml polypropylene cryovial are commonly frozen and stored using the slow freezing method. 38 In order to cryopreserve larger quantities of cells, scaleout methods could be considered. For instance, automation of vial filling and capping, using systems such as the "Fill-It" (TAP Biosystems, Royston, UK)
can be used to increase the quantities of vials prepared, whilst ensuring cells are not exposed to potentially toxic CPAs for an extended period of time.
Alternatively, a scale-up approach could be used by increasing the density of cells/ml frozen and/or increasing the size of cryocontainer. However, this strategy would represent particular technical challenges. These include ensuring sufficiently high rates of heat transfer from the larger liquid volumes and high mass transfer of CPAs into the larger cell numbers. One option is to use cryobags rather than large vials. Typically used for blood banking, these have a large surface to volume ratio and therefore facilitate the removal of latent heat from the cells during the cooling process, making them more suitable for larger scale freezing than vials. Indeed, studies have shown that significantly more than 10 6 cells at a time can be frozen by slow freezing methods using such bags. For example, 50-100 ml of 20-50x10 6 Chinese
Hamster Ovary (CHO)-S cells/ml were successfully cryopreserved in 250 ml bags. 38, 39 However, cryobags have been known to fail 40 and it is important to consider the logistics of generating cell banks or doses of cellular therapies using these. In one study 17x10 6 Baby Hamster Kidney (BHK) cells/ml were successfully preserved in 100 ml cryobags using a peristaltic pump to fill the bags at 100 ml/min and it was found that a 1.5 hour window existed in which to bank cells, using DMSO as a CPA. 41 Furthermore, bag handling can also be automated using systems such as the BioArchive ® System (ThermoGenesis Corp, CA, USA), indicating that using such bags for scale up of the slow freezing process is now possible.
Conventional slow freezing of hESCs
Although mouse ESCs can be successfully preserved by slow freezing, several studies have shown poor survival and recovery rates of hESC colonies or clumps when frozen using this protocol, quoting rates between 0-30%. 12, 15, 16, 42 For instance, in a comparative study, Li and colleagues preserved in this manner are typically >70 μm in diameter 15 and recently, it was suggested that the poor recovery noted is likely due to reduced cryoprotectant exposure of cells in the centre of the clumps leading to cell death during slow freezing. 43 Nonetheless, some studies have reported successful slow freezing of hESC colonies.
12, [44] [45] [46] For instance, when freezing conditions were partially optimised (details of which can be found in the original report), an approximately 80% survival rate of the H1 hES cell line could be achieved. 45 However, there was significant variation between runs (15%), indicating that benefits could be gained from further optimisation. One of the critical factors in attaining high hESC survival identified in this study was the inclusion of an ice seeding step at -7 to -10°C. 45 Although more systematic studies are needed which explore the role of ice seeding, and other cryobiological factors, on slow freezing of hESCs, this is consistent with other studies. 15, 47 Furthermore, another study 46 57 showed poor survival and recovery of hESC colonies when cryopreserved in feeder cell layer coated T flasks. However, these workers had greater success cryopreserving hESC colonies in tissue culture cassettes (Clinicell cassettes from Mabio
International, France). Following freezing and thawing more than 100 colonies adhered, as compared with 0-3 colonies in the tissue culture flasks, and high levels of pluripotency markers were retained.
Preserving cells in situ enables the maintenance of cell-cell connections and abolishes the need for certain processing steps such as dissociation of the cells from the surface, although it is not particularly scalable. This is due to the cost of freezing medium to cover such large surface areas and the space required to store T flasks, plates or cassettes when compared with vials.
Work also needs to be done to optimise the cooling rates achievable in such systems but it nonetheless presents an interesting opportunity to generate frozen plates of assay ready cells for use in in vitro assays such as toxicology studies.
The past five years or so has seen a number of studies developing methods for culturing hESCs on microcarriers. [59] [60] [61] [62] [63] [64] [65] [66] These provide a much larger surface area to volume ratio for not only growth but, potentially, also cryopreservation. Indeed, Nie et al. 58 demonstrated that preserving hESCs on the microcarriers they were grown on resulted in a higher recovery of undifferentiated cells compared to cells preserved in suspension.
Microcarriers are available in a variety of porosities that can enable or restrict the penetration of cells into the carrier. Notably, the microcarriers used by Nie and colleagues were microporous, meaning that cells only grew in colonies on the outer surface of the carrier and thus were not subject to any mass transfer issues such as nutrient or cryoprotectant diffusion. Although they only preserved 10 6 cells/ml in cryovials, the number of cells preserved could hopefully be increased with some optimisation. From a bioprocessing perspective, this is an interesting advance because it would reduce the number of processing steps, and hence, time. The added advantage of this technique would also be that successful differentiation of hESC on microcarriers to endoderm 60 and cardiomyocytes 67 has been reported.
Therefore cells could be grown, preserved, thawed and then differentiated on microcarriers, further cutting down on processing steps.
Given the precedent with other mammalian cell lines such as the CHO-S used in the biopharmaceutical industry, 38 there is great potential for large numbers of hESCs to be cryopreserved at once through slow freezing. However, this has yet to be reported and it remains to be seen whether it can be achieved whilst maintaining the key characteristics of these cells. Notably, much of the work discussed here, including that on the use of ROCK inhibitors, has focussed on growth of hESCs in colonies. However, single cell propagation and/or passaging would facilitate and improve not just cryopreservation but cell processing in general. Work is ongoing in this area but it has already been reported that hESCs can be grown in monolayers [7] [8] [9] or aggregate suspension, [68] [69] [70] [71] with enzymatic treatment used to dissociate cells into small clumps. Such small clumps should be more amenable to slow freezing, allowing large quantities of hESCs to be preserved at once, but little has been reported on the cryopreservation of cells grown in monolayer or suspension.
For example, Priddle and colleagues 8 reported that a conventional slow freezing protocol, without the inclusion of a Rho-kinase inhibitor, was used to preserve cells grown in monolayers but there was no mention of post-thaw recovery rates.
Cryopreservation of hESC-derived cells
Current work on hESC differentiation into clinical and research relevant cells is generally focused on either the development of differentiation protocols or improving the efficiency of existing protocols. However, some reports are emerging which look at whether hESC-derived cells can be cryopreserved using slow freezing or vitrification.
For example, human ESC-derived neurons have been successfully cryopreserved using a slow freezing technique. 72 By exposing cells to a caspase inhibitor, which aims to prevent apoptosis, recovery rates of up to 83% could be achieved. Consistent with literature on hESCs, Norström et al. 55 were able to successfully slow freeze single cell suspensions, but not clusters, of cardiomyocytes. Clumps of cardiomyocytes could, however, be preserved by using a sealed straw vitrification method. Unfortunately, in their article the authors did not specify what recovery rates were obtained. Another study revealed that when during the differentiation protocol hESC-derived cardiomyocytes were cryopreserved had a significant impact on the recovery of cell function. 73 Furthermore, they also noted that the beating frequency of cardiomyocyte clusters post-thaw was higher than that of non frozen clusters, highlighting some of the physiological changes that may occur in cells as a result of cryopreservation. It is clear that simple cell survival assays are not sufficient and that in depth analysis of cellular function post-thaw should be carried out in all studies, particularly if these cells are to be used as therapeutic agents.
Given the likely future impact of hESC-derived cells on healthcare as either cellular therapies themselves or in drug screening assays, it is particularly important that robust and consistent methods for preserving these cells are developed. Again, the scalability of such methods will be critical, particularly as some reports emerge on the expansion of hESC-derived cells and not just the differentiation protocols themselves (for example 74, 75 ). Thus, it is promising to see that in a study using a mixed cell population which included 25-59% hESC-derived cardiomyocytes, 4-8x10 7 cells per 1.5 ml cryovial could be preserved using a slow freezing protocol. 76 Recovery rates of ~75% were achieved, a promising indication that large scale preservation of hESCderived cells is feasible. However, in light of some of the physiological changes in hESC-derived cardiomyocytes noted by Kim and colleagues postthaw, much optimisation of such protocols may still be needed. It also remains to be seen whether hESC-derived cells can be frozen successfully in assay-ready plates in order to cut down on processing time if these cells are to be used in, for instance, toxicology studies.
Dry preservation: a potential alternative to cryopreservation
Whilst the use of slow freezing for the preservation of hESCs and their differentiated progeny shows the potential to be scalable, there are issues with this technique that are not related to scale and have therefore not been discussed here. For example, although DMSO is commonly used as a cryoprotectant, even in GMP-compatible solutions such as CryoStor (BioLife Solutions Inc, WA, USA), it is toxic to cells 23, 29 and can cause adverse reactions in patients. 77 Transport of vitrified cells can also be very expensive as dry shippers, which hold samples at -150°C without the risks associated with transporting liquid nitrogen, are required to prevent any partial thawing of the cells. Thus, it is important to consider whether a preservation method, such as dry preservation, which avoids the use of DMSO and results in a product that can be maintained at room temperature, would be suitable.
Dehydrating cells in a controlled manner avoids low temperature storage altogether. Generally, drying cells leads to membrane damage, protein denaturation and subsequent cell death but the natural ability of some organisms such as yeast cells and fungal spores to survive almost complete dehydration 78 suggests 'safe' dehydration and rehydration of mammalian cells should be possible. If feasible this would be both economically and practically advantageous compared to cold storage and transport as dried formulations could be stored at room temperature, although care that conditions remain stable needs to be taken. There is also a precedent, with lyophilisation of pharmaceutical-grade products occurring at a large scale, although its acceptance within the cell biology community may be more difficult.
Freeze drying, or lyophilisation, is typically used to preserve bacterial cells and fungi and involves vacuum desiccation. Briefly, there are three stages:
freezing in order to partly crystallise the solvent so that it can be separated from the solutes, sublimation of the resultant ice (primary drying phase) and finally, a secondary drying phase where the majority of the remaining moisture is removed by desorption. 78 Cells can be pre-treated with a lyoprotectant such as disaccharide sugars but nonetheless, the process can be damaging. 78, 79 Efforts to lyophilise mammalian cells have largely focused on trying to generate freeze-dried blood, with some studies showing that erythrocytes and platelets can be successfully lyophilised, stored and rehydrated, although the processes are not yet optimal. 78, 80 Although the genomic material of mouse ES cells and spermatozoa has been preserved following freeze-drying, 81 it
was not until recently that successful lyophilisation, storage for one week, and rehydration of nucleated cells was reported. 82 The authors demonstrated viability of mononuclear cells isolated from human umbilical cord blood following rehydration, with similar levels of CD34 + haematopoietic stem cells present in the population before and after preservation, which were capable of differentiating into a number of cell types. Although it remains to be seen whether lyophilised hESCs would retain their characteristics, this technique represents an interesting alternative to cryopreservation and should be explored.
Cells can also simply be dried under vacuum for example, without the need for freezing. As with lyophilisation, the introduction of a disaccharide such as trehalose, or a combination of trehalose and glycerol, into the cells offers protection from desiccation. 83 It has been shown that human mesenchymal stem cells exposed to trehalose and glycerol can be successfully dehydrated under vacuum and stored for 1 day. 84 Upon rehydration they regained their normal morphology and adhesive capability, were >90% viable, proliferated and maintained expression of key surface markers. However, the authors did admit that there was a large amount of inconsistency from trial to trial and that longer storage times would need to be achieved, again underlining the need for these techniques to be improved and optimised. Transfer of trehalose is believed to occur through both adsorption of the lipid vesicles to the erythrocyte membrane and also membrane fusion. 89 The generation of trehalose-containing, thermally-responsive, nanocapsules has enabled up to 300mM trehalose to be loaded into 3T3 fibroblasts through absorptive endocytosis. 86 However, a cold shock step was used to release trehalose from the nanocapsules intracellularly and it remains to be seen how hESCs would be affected by such treatment. Another approach has been to use a biopolymer (poly( L -lysine iso-phtalamide) backbone with Lphenylalanine attached) to increase membrane permeability of cells to trehalose. 85 The authors reported a significant increase in trehalose loaded into erythrocytes using this biopolymer, when compared to cells treated with poly( L -lysine iso-phtalamide) and trehalose or trehalose alone.
Overall, this work is encouraging and suggests that although much work would need to be done to optimise protocols for use with hESCs or hESCderived cells, dry preservation represents a potential alternative for hESC preservation. It would be a particularly attractive option for longer-term banking.
Conclusions
The recent start of some long-awaited clinical trials using hESC-derived cells in both the UK and USA highlights the potential use of these cells as therapeutic agents. Furthermore, as methods by which to produce these cells reproducibly at scale continue to be developed, their use in drug screening and toxicology assays is also set to increase. Mixed results using slow freezing to preserve hESCs have been reported.
However, this method is much more scalable than vitrification, as shown by the ability to preserve large numbers of, for example, CHO-S cells. 38 Slow freezing is also more suited to preservation of cells in single cell suspension than in colonies, which is compatible with recent developments in hESC culture processes. However, whether hESCs grown in monolayers or suspension cultures can be successfully cryopreserved (with or without the use of ROCK inhibitors), has yet to be published.
Although optimisation for use with hESCs and their differentiated progeny is undoubtedly required to retain maximum cell function, be GMP compliant and so forth, the scalability of slow freezing protocols means that it is likely to become the cryopreservation method of choice in the coming years. It will allow large numbers of cells to be frozen and stored at once if existing technologies such as cryobags and bag handling systems are exploited.
Nonetheless, as highlighted in this review, alternatives to cryopreservation, such as lyophilisation, do exist and should also be explored.
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• The osmotic imbalance may be severe enough to concentrate intracellular solutes to toxic levels.
Intracellular ice forms because insufficient dehydration has occurred.
Intracellular ice crystals may form but are too small and too few to cause damage.
Formation of extracellular ice leads to creation of an osmotic imbalance, drawing water out of the cell.
< -10°C Figure 3 . Outline of typical processing steps in conventional slow freezing and vitrification. Cells are first harvested from their culture environment. As hESCs are adherent, this involves either a mechanical or enzymatic dissociation step into either clumps or single cell suspensions. Slow freezing: cells are usually exposed to the cryopreservation medium containing CPA(s) and quickly transferred into cryocontainers (e.g. 1 ml cryovial), although stepwise addition of CPAs is sometimes done. Manual ice seeding is typically carried out before vials are then cooled at a controlled rate to at least -80°C. These are subsequently stored long term in the vapour phase of liquid nitrogen. Following rapid thawing, cells are transferred into prewarmed growth medium in order to dilute out the CPA(s). Vitrification: ~5 clumps of cells are manually transferred through at least two vitrification solutions containing CPA(s) before being placed in a cryocontainer (e.g. a cryostraw) and plunged directly into liquid nitrogen. Stepwise exposure to CPAs is used to avoid osmotic stress and toxicity. Rapid thawing is achieved by plunging the vitrified cells directly into pre-warmed media, although again several thawing media are used to 
